首页> 外文期刊>Leukemia and lymphoma >Intensified preparative regimens and allogeneic transplantation in refractory or relapsed intermediate and high grade non-Hodgkin's lymphoma.
【24h】

Intensified preparative regimens and allogeneic transplantation in refractory or relapsed intermediate and high grade non-Hodgkin's lymphoma.

机译:难治性或复发性中,高度非霍奇金淋巴瘤的强化治疗方案和同种异体移植。

获取原文
获取原文并翻译 | 示例
           

摘要

Between September 1986 and June 1998, 32 patients with relapsed or refractory intermediate or high grade lymphoma received intensified preparative therapy and underwent allogeneic transplantation at a single institution. Patients were considered for allogeneic transplantation if they failed to respond to initial therapy, failed to respond to salvage therapy, relapsed after autologous transplantation, had bone marrow involvement, or failed attempts to harvest autologous stem cells. Patients had a median age of 39 years and had generally received at least two chemotherapy regimens. Five year actuarial survival (S) was 16% +/- 6%; median survival was 4 months. Survival was significantly worse in patients who had received high intensity brief duration chemotherapy prior to transplantation and was also significantly worse in patients who did not receive total body irradiation (TBI). This likely reflects the fact that the patients with the most resistant disease had required local radiotherapy and could not receive TBI. While treatment related mortality played a major role in limiting the effectiveness of allogeneic transplantation, in this heavily pre-treated population of patients with resistant disease, only 39% of patients achieved a complete response following allogeneic transplantation, and in only 40% of that group was long term disease free survival achieved.
机译:在1986年9月至1998年6月之间,有32例复发性或难治性中度或高度淋巴瘤患者在单一机构接受强化治疗,并接受了同种异体移植。如果患者对初始治疗无效,对挽救疗法无效,自体移植后复发,骨髓受累或尝试收集自体干细胞失败,则考虑进行异体移植。患者的中位年龄为39岁,通常至少接受过两种化疗方案。五年精算生存率(S)为16%+/- 6%;中位生存期为4个月。在移植前接受高强度短期化疗的患者的生存率显着降低,而未接受全身照射(TBI)的患者的生存率也显着降低。这可能反映出以下事实:抵抗力最强的患者需要局部放疗,无法接受TBI。尽管与治疗有关的死亡率在限制同种异体移植的有效性方面起着主要作用,但在这一经过大量治疗的耐药性患者中,只有39%的患者在异种移植后达到了完全缓解,而这一组中只有40%实现了长期无病生存。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号